Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    23724867 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Nivolumab;   Drug: Ch14.18/CHO
2 Not yet recruiting Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
Condition: Acute Myeloid Leukemia and Myelodysplastic Syndrome
Interventions: Drug: Nivolumab;   Drug: Ipilimumab
3 Not yet recruiting Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Condition: Ovarian Cancer
Interventions: Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel
4 Recruiting Safety Study of Adoptive Transfer of Autologous IKDC-like Cells
Condition: Neoplasm Metastasis
Intervention: Other: autologous IKDC-like cells
5 Recruiting A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
Condition: Brain Metastases
Interventions: Drug: Fotemustine;   Drug: Fotemustine and Ipilimumab;   Drug: Ipilimumab and nivolumab
6 Active, not recruiting Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Condition: Malignant Melanoma
Interventions: Drug: BMS-936558 (MDX1106-04);   Drug: Ipilimumab

Indicates status has not been verified in more than two years